recombinant factor Xa (Andexxa)

Indications

• life-threatening or uncontrolled bleeding due to ovedose of factor Xa inhibitor (FDA-approved May 2018)

Adverse effects

• most common:
  • urinary tract infections
  • pneumonia

* boxed warning

• thromboembolism
• ischemia
• cardiac arrest

Mechanism of action

• recombinant, inactivated factor Xa
  • median decrease in anti-factor Xa activity from baseline
    • 90% for rivaroxaban, 93% for apixaban

More general terms

• coagulation factor Xa
• antidote